{"id":30543,"date":"2025-03-26T14:27:44","date_gmt":"2025-03-26T06:27:44","guid":{"rendered":"https:\/\/flcube.com\/?p=30543"},"modified":"2025-03-26T14:27:46","modified_gmt":"2025-03-26T06:27:46","slug":"cansino-biologics-partners-with-saudi-spimaco-to-boost-meningococcal-vaccine-access","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30543","title":{"rendered":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access"},"content":{"rendered":"\n

China-based CanSino Biologics Inc. (HKG: 6185<\/a>) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.<\/p>\n\n\n\n

Vaccine Demand and Features<\/strong>
The quadrivalent meningococcal conjugate vaccine has been incorporated into Saudi Arabia’s childhood immunization program, where there is a pressing need for vaccines offering longer-lasting and safer immune protection. Menhycia stimulates immunity against ACYW135 Neisseria meningitidis and is approved for use in individuals aged 3 months to 6 years. It carries advanced carrier proteins, ensuring good safety, tolerability, and immunogenicity.<\/p>\n\n\n\n

Market Strategy and Previous Collaboration<\/strong>
CanSino previously partnered with Pfizer in July 2020 for academic promotion of Menhycia in mainland China. However, this collaboration was terminated in June 2022. Since then, CanSino has taken charge of the domestic and international market strategies, as well as the planning and execution of marketing activities for Menhycia.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical…<\/p>\n","protected":false},"author":1,"featured_media":30545,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[466,884,12],"class_list":["post-30543","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cansino-biologics","tag-hkg-6185","tag-vaccine"],"yoast_head":"\nCanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30543\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access\" \/>\n<meta property=\"og:description\" content=\"China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30543\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T06:27:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T06:27:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access\",\"datePublished\":\"2025-03-26T06:27:44+00:00\",\"dateModified\":\"2025-03-26T06:27:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2607-png.webp\",\"keywords\":[\"CanSino Biologics\",\"HKG: 6185\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30543#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30543\",\"name\":\"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2607-png.webp\",\"datePublished\":\"2025-03-26T06:27:44+00:00\",\"dateModified\":\"2025-03-26T06:27:46+00:00\",\"description\":\"China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30543\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2607-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2607-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30543#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access - Insight, China's Pharmaceutical Industry","description":"China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30543","og_locale":"en_US","og_type":"article","og_title":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access","og_description":"China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.","og_url":"https:\/\/flcube.com\/?p=30543","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-26T06:27:44+00:00","article_modified_time":"2025-03-26T06:27:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30543#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30543"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access","datePublished":"2025-03-26T06:27:44+00:00","dateModified":"2025-03-26T06:27:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30543"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30543#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp","keywords":["CanSino Biologics","HKG: 6185","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30543#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30543","url":"https:\/\/flcube.com\/?p=30543","name":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30543#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30543#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp","datePublished":"2025-03-26T06:27:44+00:00","dateModified":"2025-03-26T06:27:46+00:00","description":"China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino\u2019s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30543#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30543"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30543#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp","width":1080,"height":608,"caption":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30543#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2607-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30543"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30543\/revisions"}],"predecessor-version":[{"id":30546,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30543\/revisions\/30546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30545"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}